CTI BioPharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-	-	-2.63	3.79	3.2	Upgrade
Depreciation & Amortization	-	-	0.21	0.22	0.19	Upgrade
Other Amortization	-	-	0.29	0.27	0.36	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-	0	Upgrade
Asset Writedown & Restructuring Costs	-	-	0	0	-	Upgrade
Other Operating Activities	-	-	1.28	-5.51	-6.14	Upgrade
Change in Inventory	-	-	0.29	-0.37	0.67	Upgrade
Change in Accounts Payable	-	-	-0.09	-0.08	-1.01	Upgrade
Change in Other Net Operating Assets	-	-	-0.27	0.09	-0.03	Upgrade
Operating Cash Flow	-	-	-0.91	-1.58	-2.77	Upgrade
Capital Expenditures	-	-	-0.03	-0.05	-0.16	Upgrade
Sale of Property, Plant & Equipment	-	-	-	-	0	Upgrade
Sale (Purchase) of Intangibles	-	-	-0.22	-0.01	-0.19	Upgrade
Investment in Securities	-	-	1.97	3.9	1.89	Upgrade
Other Investing Activities	-	-	-0.08	-0.6	0.22	Upgrade
Investing Cash Flow	-	-	1.53	3.03	1.88	Upgrade
Long-Term Debt Issued	-	-	0.18	0.01	0.61	Upgrade
Long-Term Debt Repaid	-	-	-0.87	-2.06	-2.4	Upgrade
Net Debt Issued (Repaid)	-	-	-0.69	-2.05	-1.79	Upgrade
Issuance of Common Stock	-	-	-	-	3.02	Upgrade
Other Financing Activities	-	-	-0.09	-0.08	-0.49	Upgrade
Financing Cash Flow	-	-	-0.78	-2.13	0.75	Upgrade
Net Cash Flow	-	-	-0.16	-0.68	-0.13	Upgrade
Free Cash Flow	-	-	-0.95	-1.63	-2.93	Upgrade
Free Cash Flow Margin	-	-	-8.30%	-16.11%	-29.71%	Upgrade
Free Cash Flow Per Share	-	-	-0.14	-0.24	-0.44	Upgrade
Cash Interest Paid	-	-	0.03	0.08	0.54	Upgrade
Cash Income Tax Paid	-	-	0.09	0.01	-0.08	Upgrade
Levered Free Cash Flow	-	-	-0.58	-1.38	-2.16	Upgrade
Unlevered Free Cash Flow	-	-	-0.51	-1.29	-2.04	Upgrade
Change in Net Working Capital	-0.86	1.62	-0.02	0.59	0.37	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.